Diagnosis and Management of Isoniazid-Induced Liver Toxicity

Diagnostic Criteria

The American Thoracic Society recommends that INH-induced hepatotoxicity is diagnosed when AST/ALT levels exceed 3 times the upper limit of normal with hepatitis symptoms, or when levels exceed 5 times the upper limit of normal even without symptoms, or when any elevation in bilirubin above normal occurs 1, 2, 3
Laboratory thresholds for diagnosis include AST/ALT ≥3× upper limit of normal (ULN) WITH symptoms of hepatitis, AST/ALT ≥5× ULN WITHOUT symptoms, and any bilirubin elevation above normal range 1, 2, 3, 4
Clinical jaundice at any transaminase level is also a diagnostic criterion 3

The Centers for Disease Control and Prevention recommends that baseline liver function tests (AST, ALT, bilirubin) are required ONLY for high-risk patients, including those with pre-existing liver disease or hepatitis B/C infection, HIV infection, pregnant women or within 3 months postpartum, regular alcohol use, concurrent hepatotoxic medications, and history of previous drug-induced liver injury 3, 4, 6
For low-risk patients with normal baseline, clinical monitoring only at monthly visits is sufficient, with no routine laboratory testing required, but patients must be educated to report symptoms immediately 3, 4, 5
For high-risk patients, weekly LFTs for the first 2 weeks, then every 2 weeks for the first 2 months, and some experts recommend even more frequent monitoring when using particularly hepatotoxic combinations 3, 4

The Infectious Diseases Society of America recommends systematically excluding viral hepatitis, biliary tract disease, alcohol use, other hepatotoxic drugs, herbal and dietary supplements, and hepatic tuberculosis itself before attributing hepatotoxicity to INH 1, 2, 4, 6

The American College of Chest Physicians recommends that when diagnostic criteria are met, immediately discontinue INH, rifampin, AND pyrazinamide, and do not wait to determine which specific drug is responsible 1, 2, 3
For patients requiring continued treatment while hepatotoxic drugs are held, switch to streptomycin plus ethambutol until liver function normalizes, or use alternative non-hepatotoxic regimens such as ethambutol with fluoroquinolone, cycloserine, and injectable agents 3, 6